Understanding IL-17's role in Bullous Pemphigoid inflammation
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study looks at how a specific immune system protein (IL-17) affects inflammation in a blistering skin disease called Bullous Pemphigoid. It aims to better understand the disease to help develop future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have Bullous Pemphigoid (a blistering skin condition) that was diagnosed with a skin biopsy and lab tests.
- You must be willing to join the study and give written consent.
- You must be covered by the French healthcare system.
- You cannot have had a previous episode of Bullous Pemphigoid (this is for first-time cases only).
- You cannot have used strong steroid creams in the last 14 days or steroid pills/injections in the last 28 days.
- You cannot have anemia (low blood count) or pemphigoid gestationis (pregnancy-related blistering).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether a simplified skin-judge score (called the Investigator Global Assessment) matches real disease severity in people with bullous pemphigoid. If your care team can score severity more easily and reliably, it may help track your response to treatment over time.
This study is for adults with certain autoimmune blistering skin conditions. Researchers want to better understand and test treatments that could improve symptoms and healing for people with these specific diseases.
This study looks at what’s happening inside the body in people with plaque psoriasis who start certain biologic medicines that target the IL-23/IL-17 immune pathway. It may help explain why these treatments work and what body changes are linked to response.
This study looks for clues in your skin and blood that could predict how well you'll respond to treatments for conditions like eczema, psoriasis, or lupus. It aims to help doctors choose the best therapy for you.
This study compares a tailored “maintenance” treatment plan to the usual standard care in adults with newly diagnosed pemphigus (PV or PF). It aims to see whether the personalized approach can help control the disease while reducing the burden of long-term treatment.
This study looks at how immune-related skin diseases like bullous pemphigoid and lupus affect blood clotting. The results could help doctors better understand and manage clotting risks in these patients.
Hear when a new Bullous Pemphigoid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.